Literature DB >> 22421946

Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.

Jianjian Jin1, Marianna Sabatino, Robert Somerville, John R Wilson, Mark E Dudley, David F Stroncek, Steven A Rosenberg.   

Abstract

Adoptive cell therapy of metastatic melanoma with autologous tumor infiltrating lymphocytes (TIL) is clinically effective, but TIL production can be challenging. Here we describe a simplified method for initial TIL culture and rapid expansion in gas-permeable flasks. TIL were initially cultured from tumor digests and fragments in 40 mL capacity flasks with a 10 cm² gas-permeable silicone bottom, G-Rex10. A TIL rapid expansion protocol (REP) was developed using 500 mL capacity flasks with a 100 cm² gas-permeable silicone bottom, G-Rex100. TIL growth was successfully initiated in G-Rex10 flasks from tumor digests from 13 of 14 patients and from tumor fragments in all 11 tumor samples tested. TIL could then be expanded to 8-10×10⁹ cells in a 2-step REP that began by seeding 5×10⁶ TIL into a G-Rex100 flask, followed by expansion at day 7 into 3 G-Rex100 flasks. To obtain the 30-60×10⁹ cells used for patient treatment, we seeded 6 G-Rex100 flasks with 5×10⁶ cells and expanded into 18 G-Rex100 flasks. Large-scale TIL REP in gas-permeable flasks requires approximately 9-10 L of media, about 3-4 times less than other methods. In conclusion, TIL initiation and REP in gas-permeable G-Rex flasks require fewer total vessels, less media, less incubator space, and less labor than initiation and REP in 24-well plates, tissue culture flasks, and bags. TIL culture in G-Rex flasks will facilitate the production of TIL at the numbers required for patient treatment at most cell processing laboratories.

Entities:  

Mesh:

Year:  2012        PMID: 22421946      PMCID: PMC3315105          DOI: 10.1097/CJI.0b013e31824e801f

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  19 in total

1.  Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.

Authors:  Juhua Zhou; Mark E Dudley; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 Jan-Feb       Impact factor: 4.456

2.  Culture of human tumor infiltrating lymphocytes in hollow fiber bioreactors.

Authors:  R A Knazek; Y W Wu; P M Aebersold; S A Rosenberg
Journal:  J Immunol Methods       Date:  1990-02-20       Impact factor: 2.303

3.  Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Authors:  Jianping Huang; Hung T Khong; Mark E Dudley; Mona El-Gamil; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

4.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

5.  Large-scale bioreactor expansion of tumor-infiltrating lymphocytes.

Authors:  Arian Sadeghi; Linnea Pauler; Cecilia Annerén; Andrew Friberg; Daniel Brandhorst; Olle Korsgren; Thomas H Tötterman
Journal:  J Immunol Methods       Date:  2010-11-25       Impact factor: 2.303

6.  Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.

Authors:  C C Malone; P M Schiltz; A D Mackintosh; L D Beutel; F S Heinemann; R O Dillman
Journal:  Cancer Biother Radiopharm       Date:  2001-10       Impact factor: 3.099

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.

Authors:  Mark E Dudley; John R Wunderlich; Thomas E Shelton; Jos Even; Steven A Rosenberg
Journal:  J Immunother       Date:  2003 Jul-Aug       Impact factor: 4.456

9.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

Authors:  S A Rosenberg; J R Yannelli; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  J Natl Cancer Inst       Date:  1994-08-03       Impact factor: 13.506

10.  In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.

Authors:  D J Schwartzentruber; S S Hom; R Dadmarz; D E White; J R Yannelli; S M Steinberg; S A Rosenberg; S L Topalian
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

View more
  43 in total

1.  Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Authors:  Mark E Dudley; Colin A Gross; Robert P T Somerville; Young Hong; Nicholas P Schaub; Shannon F Rosati; Donald E White; Debbie Nathan; Nicholas P Restifo; Seth M Steinberg; John R Wunderlich; Udai S Kammula; Richard M Sherry; James C Yang; Giao Q Phan; Marybeth S Hughes; Carolyn M Laurencot; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

Review 2.  Overcoming Challenges in Process Development of Cellular Therapies.

Authors:  Steven L Highfill; David F Stroncek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Authors:  Sanja Stevanović; Lindsey M Draper; Michelle M Langhan; Tracy E Campbell; Mei Li Kwong; John R Wunderlich; Mark E Dudley; James C Yang; Richard M Sherry; Udai S Kammula; Nicholas P Restifo; Steven A Rosenberg; Christian S Hinrichs
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

4.  Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Jiang Li; Qiu-Yan Chen; Jia He; Ze-Lei Li; Xiao-Feng Tang; Shi-Ping Chen; Chuan-Miao Xie; Yong-Qiang Li; Li-Xi Huang; Shu-Bio Ye; Miao-La Ke; Lin-Quan Tang; Huai Liu; Lu Zhang; Shan-Shan Guo; Jian-Chuan Xia; Xiao-Shi Zhang; Li-Min Zheng; Xiang Guo; Chao-Nan Qian; Hai-Qiang Mai; Yi-Xin Zeng
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

5.  Dendritic cells: an immunotherapy coming of age.

Authors:  David F Stroncek; Francisco M Marincola
Journal:  Immunotherapy       Date:  2012-10       Impact factor: 4.196

6.  Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers.

Authors:  Maria R Parkhurst; Paul F Robbins; Eric Tran; Todd D Prickett; Jared J Gartner; Li Jia; Gabriel Ivey; Yong F Li; Mona El-Gamil; Almin Lalani; Jessica S Crystal; Abraham Sachs; Eric Groh; Satyajit Ray; Lien T Ngo; Scott Kivitz; Anna Pasetto; Rami Yossef; Frank J Lowery; Stephanie L Goff; Winifred Lo; Gal Cafri; Drew C Deniger; Parisa Malekzadeh; Mojgan Ahmadzadeh; John R Wunderlich; Robert P T Somerville; Steven A Rosenberg
Journal:  Cancer Discov       Date:  2019-06-04       Impact factor: 39.397

7.  Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer.

Authors:  Yasmine Assadipour; Nikolaos Zacharakis; Jessica S Crystal; Todd D Prickett; Jared J Gartner; Robert P T Somerville; Hui Xu; Mary A Black; Li Jia; Harshini Chinnasamy; Isaac Kriley; Lily Lu; John R Wunderlich; Zhili Zheng; Yong-Chen Lu; Paul F Robbins; Steven A Rosenberg; Stephanie L Goff; Steven A Feldman
Journal:  Clin Cancer Res       Date:  2017-04-04       Impact factor: 12.531

Review 8.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

Review 9.  Chimeric antigen receptor-redirected T cells return to the bench.

Authors:  Claudia Geldres; Barbara Savoldo; Gianpietro Dotti
Journal:  Semin Immunol       Date:  2016-01-12       Impact factor: 11.130

Review 10.  CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Renier J Brentjens
Journal:  Clin Adv Hematol Oncol       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.